Personalized mRNA Cancer Vaccines: Advances, Limitations, and the Promise of mRNA-4157 (V940)

Abstract

mRNA-4157 (V940) is an individualized cancer vaccine designed to stimulate potent immune responses against patient-specific tumor neoantigens. Building on the rapid design capability, safety profile, and immunogenicity demonstrated by mRNA vaccines during the COVID-19 pandemic, V940 represents a significant advance in personalized immunotherapy. It is generated through sequencing of tumor and matched normal tissues, computational prediction of up to 34 top-ranked neoantigens, and formulation of an optimized mRNA construct in lipid nanoparticles. Once delivered, the mRNA is translated in host antigen-presenting cells, initiating antigen processing, presentation, and activation of CD8⁺ and CD4⁺ T cells that target tumor cells carrying those mutations. Advantages include rapid design cycles, polyepitope targeting, and a non-integrating platform, while challenges include time-sensitive manufacturing, cold chain requirements, imperfect neoantigen prediction, reduced efficacy in low-mutation-burden tumors, and the immunosuppressive tumor microenvironment. Current development focuses on refining antigen prediction algorithms, combining with synergistic therapies such as checkpoint inhibitors, radiation, or innate agonists, and expanding use into earlier-stage cancers. V940’s modular, mutation-guided approach offers a template for future cancer vaccines and the potential to transform treatment paradigms across multiple malignancies.